Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06775041 · ClinicalTrials.gov registry record · Phase 2
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
A Phase 2 study of Hutchinson-Gilford Progeria Syndrome, sponsored by PRG Science & Technology Co..
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06775041: Active Phase 2 study of Hutchinson-Gilford Progeria Syndrome, sponsored by PRG Science & Technology Co..
NCT06775041 is a Phase 2 study of Hutchinson-Gilford Progeria Syndrome that is active but no longer recruiting, run by PRG Science & Technology Co.. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06775041, a Phase 2 study of Hutchinson-Gilford Progeria Syndrome, is active but no longer recruiting, sponsored by PRG Science & Technology Co..
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.
Conditions Studied
Interventions
- DRUG Progerinin
- DRUG Lonafarnib
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-01-13 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
What the registry record for NCT06775041 still lists
NCT06775041 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Hutchinson-Gilford Progeria Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Progerinin is the first listed.
NCT06775041 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06775041 about?
NCT06775041 is a clinical study titled "Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)". Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (...
What is the current status of trial NCT06775041?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-01-13. Estimated completion is 2026-03.
What conditions does trial NCT06775041 study?
This clinical trial studies the following conditions: Hutchinson-Gilford Progeria Syndrome.
What interventions are being tested in trial NCT06775041?
The interventions under investigation include: Progerinin (DRUG), Lonafarnib (DRUG).
Who is sponsoring clinical trial NCT06775041?
This trial is sponsored by PRG Science & Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06775041 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hutchinson-Gilford Progeria Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06775041's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI